Analysts Offer Predictions for BCYC FY2025 Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Bicycle Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the company will earn ($4.24) per share for the year. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.05) per share.

A number of other brokerages have also commented on BCYC. JMP Securities cut their price target on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a report on Wednesday, December 18th. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 price target on shares of Bicycle Therapeutics in a research report on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and set a $35.00 price objective on shares of Bicycle Therapeutics in a research report on Friday, November 1st. B. Riley reduced their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Finally, Stephens restated an “equal weight” rating and set a $15.00 price target on shares of Bicycle Therapeutics in a report on Wednesday. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Bicycle Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.25.

Bicycle Therapeutics Price Performance

BCYC opened at $12.98 on Thursday. Bicycle Therapeutics has a fifty-two week low of $12.17 and a fifty-two week high of $28.67. The company’s 50 day moving average price is $16.56 and its two-hundred day moving average price is $21.23. The firm has a market capitalization of $896.27 million, a price-to-earnings ratio of -3.95 and a beta of 0.92.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.04. The company had revenue of $2.68 million for the quarter, compared to analysts’ expectations of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business’s quarterly revenue was down 50.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.26) earnings per share.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Renaissance Technologies LLC raised its holdings in shares of Bicycle Therapeutics by 97.2% in the 2nd quarter. Renaissance Technologies LLC now owns 326,800 shares of the company’s stock worth $6,614,000 after acquiring an additional 161,100 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Bicycle Therapeutics in the second quarter worth approximately $206,000. Marshall Wace LLP purchased a new stake in shares of Bicycle Therapeutics in the second quarter worth approximately $1,801,000. Cubist Systematic Strategies LLC lifted its holdings in shares of Bicycle Therapeutics by 923.5% in the second quarter. Cubist Systematic Strategies LLC now owns 96,409 shares of the company’s stock valued at $1,951,000 after purchasing an additional 86,989 shares in the last quarter. Finally, Armistice Capital LLC boosted its position in shares of Bicycle Therapeutics by 17.9% during the second quarter. Armistice Capital LLC now owns 1,972,000 shares of the company’s stock valued at $39,913,000 after buying an additional 300,000 shares during the last quarter. 86.15% of the stock is owned by institutional investors.

Insider Buying and Selling at Bicycle Therapeutics

In related news, CAO Travis Alvin Thompson sold 6,256 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $25.11, for a total transaction of $157,088.16. Following the transaction, the chief accounting officer now directly owns 19,241 shares of the company’s stock, valued at approximately $483,141.51. This represents a 24.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bros. Advisors Lp Baker acquired 985,397 shares of the firm’s stock in a transaction dated Friday, December 13th. The shares were purchased at an average price of $13.76 per share, with a total value of $13,559,062.72. Following the acquisition, the director now owns 9,537,643 shares of the company’s stock, valued at approximately $131,237,967.68. This represents a 11.52 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 33,933 shares of company stock valued at $549,501. 8.50% of the stock is currently owned by company insiders.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.